<DOC>
	<DOCNO>NCT02130401</DOCNO>
	<brief_summary>This pilot study single active treatment arm . The study design assess efficacy portable , non-invasive neuromodulation system treatment Type 2 Diabetes . In particular , primary outcome measure reduction A1c .</brief_summary>
	<brief_title>Examining Effects Neuromodulation Glucose Metabolism Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion Criteria A subject eligible study follow criterion meet : Provide write informed consent prior enrollment . Is male female 1870 year old . Has diagnose type II diabetes great 12 month . Is currently either use lifestyle modification take one two follow oral antihyperglycemic agent stable dos 90 day prior screen : metformin DPP4 inhibitor ( sitagliptin , saxagliptin , alogliptin , linaglyptin ) Pioglitazone GLP1 agonist ( exenatide , liraglutide , exenatide LAR ) SGLT2 Inhibitors ( dapaglifozin , canagliflozin ) Has A l c 7.5 9.0 % base upon point care test perform visit 1 . Currently perform selfmonitoring blood glucose check least 3 time per week . Able adhere protocol requirement . Exclusion Criteria A subject exclude follow criterion meet : Has Type 1 Diabetes Gestational Diabetes . Is pregnant plan become pregnant course study . Current use OR use past 6 month sulfonylureas . Current use OR use past 6 month insulin History cardiovascular disease cerebrovascular disease . Any planned surgery course study . Current continuous renal replacement therapy . Current oral injectable steroid use use within previous 3 month . Previous current treatment deep brain stimulation . Any previous know disease , injury , surgical intervention involve brain central nervous system . Moderate great hearing loss . Presence cochlear implant . Diagnosed vestibular dysfunction . Eye surgery within previous three month . Any history previous ear surgery . Active ear infection perforate tympanic membrane . Presence serious unstable medical psychological condition , opinion investigator , would compromise subject 's safety successful participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>neuromodulation</keyword>
	<keyword>caloric vestibular stimulation</keyword>
	<keyword>Type 2 Diabetes</keyword>
</DOC>